Evidence map›Paper›PMID 32213623›Full record

ArticlemSphere2020

HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy.

Alan D Curtis, Maria Dennis, Joshua Eudailey, Korey L Walter, Kenneth Cronin, S Munir Alam, Neelima Choudhary, Ryan H Tuck, Michael Hudgens, Pamela A Kozlowski and 5 more

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Alan D CurtisDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Maria DennisDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Joshua EudaileyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Korey L WalterDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Kenneth CroninDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Neelima ChoudharyDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ryan H TuckDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael HudgensDepartment of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Pamela A KozlowskiDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Justin PollaraDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Koen K A Van RompayCalifornia National Primate Research Center, University of California at Davis, Davis, California, USA.ORCID 0000-0002-7375-1337
Sallie PermarDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Kristina De ParisDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA abelk@med.unc.edu.
University of North Carolina at Chapel Hill · USDuke Medical Center · USDuke University · USLouisiana State University Health Sciences Center New Orleans · USUniversity of California, Davis · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responsesP01AI117915 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE PARIS, KRISTINA, PERMAR, SALLIE R. · 2015 to 2024
$21.2M
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0M
NIAID NIH HHS P01 AI117915NIAID NIH HHS P30 AI050410NIH HHS K01 OD024877NIH HHS P51 OD011107
6 · The paper itself

Abstract

The HIV epidemics in infants and adolescent women are linked. Young women of childbearing age are at high risk for HIV infection and, due to poor HIV testing rates and low adherence to antiretroviral therapy, are at high risk for mother-to-infant transmission. We hypothesize that HIV vaccine regimens initiated in early life would provide the necessary time frame to induce mature and highly functional Env-specific antibody responses that could potentially also protect against HIV acquisition later in life. The present study was designed to test two vaccine regimens, a clade C HIV Env protein vaccine (Env only) alone or combined with a modified vaccinia Ankara (MVA) vector expressing HIV Env (MVA/Env) for the induction and persistence of Env-specific antibody responses in an infant nonhuman primate model. Vaccination was initiated within the first week of life, with booster immunizations at weeks 6, 12, and 32. We demonstrate that both vaccine strategies were able to elicit durable Env-specific antibody responses that were enhanced by a late boost in infancy. Furthermore, we confirmed earlier data that intramuscular administration of the Env protein with the Toll-like receptor 7/8 (TLR7/8)-based adjuvant 3M-052 in stable emulsion (3M-052-SE) induced higher Env-specific antibody responses than vaccination with Env adjuvanted in Span85-Tween 80-squalene (STS) tested in a previous study. These results support the concept of early vaccination as a means to induce durable immune responses that may prevent HIV infection in adolescence at the onset of sexual debut.

Indexed as

Immunization, SecondaryAdjuvants, ImmunologicAIDS VaccinesAnimalsAnimals, NewbornAntibodies, NeutralizingFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsImmunization ScheduleImmunoglobulin GMacaca mulattaMaleVaccinationAdjuvants, ImmunologicAIDS VaccinesAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin GadjuvantHIVmemory antibody responsespediatric vaccination

Identifiers

PMID32213623
PMCPMC7096624
OpenAlexW3013567812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.